



16<sup>th</sup> March 2021

The Secretary  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai 400 001

The Secretary  
The National Stock Exchange of India  
Limited  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/1, G Block  
Bandra-Kurla Complex  
Bandra East,  
Mumbai 400 050

**Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)**

Dear Sirs

The audited financial results of the Company for the quarter and year ended 31<sup>st</sup> December 2020 were approved by the Board of Directors of the Company at its meeting held on 23<sup>rd</sup> February 2021 and published on 25<sup>th</sup> February 2021. Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed the disclosures of related party transactions for the half year ended 31<sup>st</sup> December 2020 in the format specified in the applicable accounting standards.

Kindly take the above information on record.

Thanking you,

Yours faithfully

For SANOFI INDIA LIMITED

A handwritten signature in blue ink, appearing to read "Girish Tekchandani", written over a horizontal line.

GIRISH TEKCHANDANI  
COMPANY SECRETARY

**Related Party Disclosures****i. Parties where control exists:**

- a) Sanofi S.A. France, ultimate holding Company
- b) Hoechst GmbH, Germany, holding Company

**ii. Other related parties in Sanofi Group where common control exists and with whom transactions have taken place during the period.**

Sanofi-Aventis Singapore Pte. Limited  
 Francopia S.A.R.L.  
 Sanofi-Aventis Groupe S.A.  
 Sanofi-Aventis Deutschland GmbH  
 Sanofi Lanka Limited  
 Sanofi-aventis Philippines Inc.  
 Sanofi Pasteur India Private Limited  
 Sanofi-Synthelabo (India) Private Limited  
 Sanofi Winthrop Industrie S.A.  
 Sanofi-Aventis Pakistan Limited  
 Sanofi Healthcare India Private Limited (Formerly Shantha Biotechnics Private Limited)  
 Sanofi India Limited Provident Fund

**iii. Key management personnel of the Company for the year**

- Mr. Rajaram Narayanan - Managing Director
- Mr. Cherian Mathew - Whole Time Director
- Mr. Vaibhav Karandikar - Chief Financial officer (w.e.f October 06, 2020) and Whole time director (w.e.f February 23, 2021)
- Mr. Girish Tekchandani - Company Secretary
- Mr. Charles Billard - Whole Time Director and CFO (till the closure of business of September 30, 2020)

**iv. Non-Executive Directors**

- Mr. Cyril Grandchamp-Desraux
- Mr. Thomas Rouckout (till the closure of business of February 25, 2020)
- Dr. Shallesh Ayyangar (till the closure of business of February 25, 2020)
- Mr. Marc-Antoine Lucchini (w.e.f July 29, 2020)
- Mr. Charles Billard (w.e.f October 01, 2020)

**v. Independent Directors**

- Mr. Aditya Narayan
- Mr. Rangaswamy Iyer (till the closure of business of March 30, 2020)
- Mrs. Usha Thorat
- Mr. Rahul Bhatnagar (w.e.f July 29, 2020)

**vi. Transactions during the year**

(₹ in Million)

Particulars	July- Dec 2020
<b>Ultimate Holding Company</b>	
Dividend paid	2
Expenses recharged	26
<b>Total</b>	<b>28</b>
<b>Holding Company</b>	
Dividend paid	4,853
<b>Other related Parties</b>	
<b>Sale of Products and Other Operating Income</b>	
Sanofi-Aventis Singapore Pte. Limited	2,080
Others	165
<b>Total</b>	<b>2,245</b>
<b>Purchase of Raw Materials and Stock- in- trade</b>	
Sanofi-Aventis Singapore Pte. Limited	2,859
Francopia S.A.R.L.	818
Others	160
<b>Total</b>	<b>3,837</b>
<b>Expenses recharged to other companies</b>	
Sanofi-Aventis Singapore Pte. Limited	-
Sanofi-Aventis Groupe S.A.	2
Sanofi-Synthelabo (India) Private Limited	37
Sanofi-Aventis Singapore Pte. Limited	109
Sanofi Pasteur India Private Limited	8
Others	2
<b>Total</b>	<b>158</b>
<b>Sale of Services</b>	
Sanofi-Synthelabo (India) Private Limited	492
Sanofi Pasteur India Private Limited	187
Sanofi Winthrop Industrie S.A.	0
Sanofi-Aventis Singapore Pte. Limited	41
Others	6
<b>Total</b>	<b>726</b>
<b>Sale of property, plant and equipment</b>	
Sanofi-Synthelabo (India) Private Limited	*
<b>Total</b>	<b>*</b>
<b>Rent Income</b>	
Sanofi Healthcare India Private Limited (Formerly Shantha Biotechnics Private Limited)	*
Sanofi-Synthelabo (India) Private Limited	*
<b>Total</b>	<b>*</b>
<b>Rent Paid</b>	
Sanofi Healthcare India Private Limited (Formerly Shantha Biotechnics Private Limited)	*
<b>Loans given</b>	
Sanofi Pasteur India Private Limited	-
<b>Total</b>	<b>-</b>
<b>Loans repaid</b>	
Sanofi Pasteur India Private Limited	400
<b>Total</b>	<b>400</b>

(₹ in Million)

Particulars	July- Dec 2020
<b>Interest income on loans</b>	
Sanofi Healthcare India Private Limited (Formerly Shantha Biotechnics Private Limited)	168
Sanofi Pasteur India Private Limited	7
<b>Total</b>	<b>175</b>
<b>Expenses recharged by other companies</b>	
Sanofi-Synthelabo (India) Private Limited	25
Sanofi Winthrop Industrie S.A.	150
Sanofi Lanka Limited	58
Sanofi-Aventis Groupe S.A.	32
Others	12
<b>Total</b>	<b>277</b>
<b>Contribution to In-house Trust for Post Employment Benefits - Provident Fund</b>	
Sanofi India Limited Provident Fund #	148
<b>Payment towards Intangibles under development</b>	
Sanofi-Synthelabo (India) Private Limited	1

# Including contribution by employees.

(₹ in Million)

Particulars	July- Dec 2020
<b>Key Management Personnel Remuneration # #</b>	
<b>Remuneration</b>	
Mr. Rajaram Narayanan	21
Mr. Charles Billard	6
Mr. Vaibhav Karandikar	5
Mr. Cherian Mathew	13
Mr. Girish Tekchandani	6
<b>Total</b>	<b>51</b>
<b>Share based benefit</b>	
Mr. Rajaram Narayanan	11
Mr. Vaibhav Karandikar	*
Mr. Charles Billard	(3)
Mr. Cherian Mathew	5
<b>Total</b>	<b>13</b>

# # Excludes Provision for Employee Benefits

(₹ in Million)

Particulars	July- Dec 2020
<b>Sitting Fees to Non- Executive Directors</b>	
Mr. Aditya Narayan	*
Mr. Rangaswamy R. Iyer	*
Ms. Usha Thorat	*
Dr. Shailesh Ayyangar	*
Mr. Rahul Bhatnagar	*
<b>Total</b>	<b>1</b>
<b>Commission to Non - Executive Directors</b>	
Mr. Aditya Narayan	1
Mr. Rangaswamy R. Iyer	*
Ms. Usha Thorat	*
Dr. Shailesh Ayyangar	*
Mr. Rahul Bhatnagar	*
<b>Total</b>	<b>2</b>

\* denotes figure less than a million

#### Terms and conditions of transactions with related parties

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. For the year ended December 31, 2020, the Company has not recorded any impairment of receivables relating to amounts owed by related parties (December 31, 2019: Nil). This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

(₹ in Million)

Particulars	December 30, 2020
<b>Trade Receivables</b>	
Sanofi-Aventis Singapore Pte. Limited	708
Sanofi-Synthelabo (India) Private Limited	185
Others	115
<b>Total</b>	<b>1,008</b>
<b>Trade Payables</b>	
Sanofi-Aventis Singapore Pte. Limited	805
Sanofi Winthrop Industrie S.A.	154
Francopia S.A.R.L.	303
Others	242
<b>Total</b>	<b>1,504</b>
<b>Others Receivables</b>	
Sanofi-Synthelabo (India) Private Limited	4
Sanofi Pasteur India Private Limited	4
<b>Total</b>	<b>8</b>
<b>Loans receivable</b>	
Sanofi Healthcare India Private Limited (Formerly Shantha Biotechnics Private Limited) (Refer Note 1 below)	4,450

1) Loans given to Sanofi Healthcare India Private Limited (Formerly Shantha Biotechnics Private Limited) at the rate of interest of 7.5% p.a (9.5 % till April 14 , 2020).

Maximum balance outstanding during the year ₹ 4,450 Million ( December 31, 2019 : ₹ 4,450 Million) from Sanofi Healthcare India Private Limited (Formerly Shantha Biotechnics Private Limited).

The said loans have been proposed to be utilized by Sanofi Healthcare India Private Limited (Formerly Shantha Biotechnics Private Limited) for business purpose.

The Loans have been given against corporate guarantee by Sanofi S.A. France. The Maturity date of same is April 15, 2022.